Epithelial-mesenchymal transition (EMT) programs are essential in promoting breast cancer invasion, systemic dissemination and in arousing proliferative programs in breast cancer micrometastases, a reaction that is partially dependent on focal adhesion kinase (FAK). Many functions of FAK are shared by its homolog, protein tyrosine kinase 2 (Pyk2), raising the question as to whether Pyk2 also participates in driving the metastatic outgrowth of disseminated breast cancer cells. In addressing this question, we observed Pyk2 expression to be (i) significantly upregulated in recurrent human breast cancers; (ii) differentially expressed across clonal isolates of human MDA-MB-231 breast cancer cells in a manner predictive for metastatic outgrowth, but not for invasiveness; and (iii) dramatically elevated in ex vivo cultures of breast cancer cells isolated from metastatic lesions as compared with cells that produced the primary tumor. We further show that metastatic human and murine breast cancer cells robustly upregulate their expression of Pyk2 during EMT programs stimulated by transforming growth factor-b (TGF-b). Genetic and pharmacological inhibition of Pyk2 demonstrated that the activity of this protein tyrosine kinase was dispensable for the ability of breast cancer cells to undergo invasion in response to TGF-b, and to form orthotopic mammary tumors in mice. In stark contrast, Pyk2-deficiency prevented TGF-b from stimulating the growth of breast cancer cells in 3D-organotypic cultures that recapitulated pulmonary microenvironments, as well as inhibited the metastatic outgrowth of disseminated breast cancer cells in the lungs of mice. Mechanistically, Pyk2 expression was inversely related to that of E-cadherin, such that elevated Pyk2 levels stabilized b1 integrin expression necessary to initiate the metastatic outgrowth of breast cancer cells. Thus, we have delineated novel functions for Pyk2 in mediating distinct elements of the EMT program and metastatic cascade regulated by TGF-b, particularly the initiation of secondary tumor outgrowth by disseminated cells.
INTRODUCTION
Transforming growth factor-b (TGF-b) and its induction of epithelial-mesenchymal transition (EMT) are essential mediators underlying the acquisition of invasive and metastatic phenotypes in breast cancers. Recent findings have begun to delineate the molecular mechanisms whereby EMT programs are stimulated by TGF-b, which targets a variety of transcription factors and microRNAs that collectively induce polarized epithelial cells to acquire apolar mesenchymal-like characteristics. 1, 2 Along these lines, we recently established the essential function of integrins and focal adhesion complexes in mediating oncogenic TGF-b signaling and its coupling to EMT programs (see Wendt et al. 1 and Taylor et al.
2 ). Indeed, formation of TbR-II:b3 integrin complexes amplifies the transduction through a Src:(focal adhesion kinase) FAK:Grb2:p38 MAPK signaling axis coupled to the initiation of EMT and metastasis in breast cancers (see Wendt et al. 1 and Taylor et al.
2 ). Despite these recent advances, science and medicine still know very little as to how the progression through and eventual emergence from an EMT program impacts the flux through cellular signaling systems. Two recent studies by our group have attempted to address this question and demonstrated that breast cancer cells that have undergone EMT possess a selective advantage to (i) escape the confines of the primary tumor via an EGF-dependent mechanism, 3 and (ii) circumvent the inhibitory actions of E-cadherin (E-cad) in suppressing b1 integrin expression necessary to reinitiate proliferative programs and metastatic outgrowth. 4 Collectively, these findings provided novel insights into the functions of TGF-b and EMT in supporting late events of the metastatic cascade; however, the identity and relative contribution of specific TGF-b effectors in mediating these events remains to be fully elucidated.
Protein tyrosine kinase 2 (Pyk2; also known as CAKB, FAK2, CADTK, FADK2 or RAFTK) is a homolog of FAK and shares an overall amino acid identity of 46%, which increases to 60% within the protein tyrosine kinase domain. 5, 6 Despite their structural similarities, FAK and Pyk2 exhibit important functional differences. For instance, FAK expression is ubiquitous, essential for life and localizes primarily to focal adhesion complexes where it is activated by integrins and growth factor receptors. In stark contrast, the expression of Pyk2 is highly restricted, dispensable for life, and localizes primarily to the cytoplasm where it is activated by chemokines and G protein-coupled receptors.
Although both protein tyrosine kinases are known to regulate cell migration and invasion in a compensatory manner, [12] [13] [14] [15] the differences existing in their tissue distribution, subcellular localization, and necessity for survival indicate that FAK and Pyk2 have unique roles in regulating cell and tissue homeostasis. 9, 16, 17 With respect to breast cancers, we 18 and others [19] [20] [21] [22] have identified FAK as a key factor operant in coupling TGF-b to EMT, invasive and metastatic behaviors. However, the expression and activity of Pyk2 has also been implicated in regulating the production and expansion of breast cancer stem cells, 13 as well as in promoting the motility and survival of breast cancer cells. 13, 23, 24 Herein, we identify Pyk2 as a novel EMT biomarker and found its expression to be robustly upregulated by TGF-b in transdifferentiating breast cancer cells. Thus, the objective of this study was to determine the mechanism whereby Pyk2 contributes to breast cancer metastasis.
RESULTS

Pyk2 expression is elevated in aggressive breast cancers
Although elevations in the expression and activity of FAK are clearly associated with breast cancer progression and metastasis, [18] [19] [20] [21] [22] a similar understanding related to the function of Pyk2 during mammary tumorigenesis remains to be elucidated. As such, we performed Oncomine 4.4 analyses and observed Pyk2 expression to be significantly upregulated in H-Ras-transformed mammary epithelial cells, and in invasive human breast carcinomas, particularly those that exhibited recurrence (Table 1) . Moreover, Pyk2 expression was significantly reduced in human MDA-MB-231 (MDA-231) metastatic breast cancer cells engineered to lack expression of Coco, 25 a bone morphogenetic protein antagonist (GSE28049; Table 1 ). Bone morphogenetic protein and TGF-b signaling typically oppose one another, particularly during the induction of EMT programs. 4 Therefore, this finding suggests that expression of Pyk2 may reflect the overall balance of signaling inputs originating from TGF-b and Bone morphogenetic protein.
Along these lines, we monitored Pyk2 expression levels in parental and clonal cell populations of MDA-231 cells (Figure 1a ), which were established from a pleural effusion and represent a heterogeneous mixture of aggressive and nonaggressive carcinoma cells. 26 Interestingly, while FAK expression was equivalent across all MDA-231 clonal populations, we observed Pyk2 expression to be highly variable and dissociated from the differential invasiveness exhibited by these clonal populations (Figures 1a and b) . However, Pyk2 expression was positively associated with the competency of MDA-231 cells to thrive in 3D-organotypic cultures that mimicked the pulmonary microenvironment. Indeed, Figure 1c shows that Pyk2-positive CP2-MDA-231 cells grew robustly in 3D-cultures, while Pyk2-deficient CP4-MDA-231 cells grew poorly and displayed loosely packed and branched organoid structures that we previously linked to the development of metastatic dormancy (Figure 1d) . 3, 4 It should be noted that FAK activation has also been implicated as a mediator of metastatic outgrowth. 27 Thus, to gage the extent to which FAK or Pyk2 activity drives the outgrowth of metastatic breast cancer cells, we compared the activities of two related FAK and Pyk2 antagonists, PF562271 (PF-271) and PF573228 (PF-228). Importantly, while PF-271 and PF-228 are equivalent in their ability to inhibit FAK (IC50 of 1.5 and 4 nM, respectively), these compounds differ significantly in their ability to inhibit Pyk2 (IC50 of 14 and 1000 nM, respectively). 28, 29 Administration of the dual FAK/Pyk2 inhibitor, PF-271, was significantly more effective at inhibiting the 3D-outgrowth of CP2-MDA-231 cells as compared with equivalent concentrations of the FAK-specific inhibitor, PF-228 (Figures 1d  and e) . Collectively, these findings implicate elevated Pyk2 expression and activity as a potential mediator of metastatic outgrowth by breast cancer cells.
TGF-b induces Pyk2 expression via Smad4-and Src-dependent pathways Given the strong correlation between elevated Pyk2 expression and breast cancer progression (Table 1 and Figure 1 ), we next sought to determine whether and how TGF-b coupled to Pyk2 in metastatic breast cancers. Figure 2a shows that TGF-b readily induced Pyk2 expression in MDA-231 cells propagated in traditional 2D-cultures, and that the magnitude of Pyk2 expression was potentiated by propagating MDA-231 cells in compliant 3D-organotypic cultures. Likewise, we also observed Pyk2 expression to increase as a function of the metastatic ability of derivatives belonging to the murine 4T1 breast cancer progression series (Supplementary Figure 1a) . 30 Indeed, the tonic levels of Pyk2 mRNA and protein were significantly higher in 4T1 cells as compared with their less aggressive 4T07 counterparts (Figures 2b  and c) . Moreover, both cell lines rapidly and dramatically upregulated their synthesis of Pyk2 transcripts and protein when stimulated by TGF-b (Figures 2b and c) . Importantly, increases in Pyk2 expression were paralleled by elevations in its phosphorylation status (Supplementary Figure 1b) . Furthermore, administration of TbR-I or Src inhibitors to 4T1 cells suppressed their expression of Pyk2, thereby implicating autocrine TGF-b signaling and its activation of Src [31] [32] [33] as drivers of elevated Pyk2 expression in metastatic breast cancer cells (Figure 2d ). It is interesting to note that TGF-b failed to upregulate Pyk2 expression in nonmetastatic and dormant human MCF-7 cells (Supplementary Figure 1c) , but readily did so in our recently established model of EGFR-mediated transformation and EMT-driven metastatic progression of normal murine mammary gland cells (Supplementary Figure 1d) . 3, 4 Collectively, these findings suggest that the extent Figure 2c) . Taken together, these data suggest that Pyk2 may represent a novel and specific target of TGF-b-induced EMT.
Finally, we sought to delineate the mechanisms whereby TGF-b stimulates the expression of Pyk2. Supplementary Figure 2d shows that the ability of TGF-b to induce Pyk2 expression was blocked by Pyk2 expression is essential for pulmonary tumor formation in mice Our aforementioned findings suggest that Pyk2 may have a critical role in facilitating breast cancer metastasis. Therefore, we depleted Pyk2 expression in highly metastatic 4T1 cells, which then were engrafted onto the mammary fat pads of Balb/C mice ( Figure 3a) . Although Pyk2-deficiency failed to affect the growth and latency of primary 4T1 tumors (Figure 3b ), this same cellular condition did significantly impair the extent and size to which disseminated 4T1 cells formed macroscopic pulmonary metastases (Figures 3c and d) .
We also examined the necessity of Pyk2 in regulating the metastatic ability of 4T07 cells, which dramatically upregulate their expression of this protein tyrosine kinase in response to TGF-b (Figure 2 ). Although 4T07 cells are capable of forming and exiting a primary orthotopic tumor and being readily detected in the circulatory system of mice, these cells cannot establish proliferating secondary tumors at disseminated organ sites. 3, 30 However, when injected into the lateral tail vein of Balb/C mice, 4T07 cells exhibited widespread dissemination and aggressive colonization of multiple tissues, including the brain (data not shown), lung and various skeletal sites (Figure 4a; Supplementary Figure 4a) . Importantly, Pyk2 expression was uniformly upregulated in ex vivo cultures of 4T07 metastases as compared their parental counterparts (Figure 4b; Supplementary Figure 4b (Figure 5a ). However, despite the morphological similarities observed in these static photomicrographs, time-lapse microscopy showed that administration of PF-228 inhibited the motility of 4T07 cells by preventing their ability to turnover focal adhesion complexes ( Supplementary Movies  1-3) . 29, 38, 39 In stark contrast, we observed EMT induced by TGFb to significantly enhance the invasion (Figure 5b ) and migration (Supplementary Movie 2) of 4T07 cells. Interestingly, pharmacological inhibition of FAK (PF-228) or FAK/Pyk2 (PF-271) similarly prevented 4T07 cells from acquiring invasive phenotypes in response to TGF-b (Figure 5b) , an event reminiscent of the failure of TGF-b to induce the invasion of FAK-deficient breast cancer cells. 18 Collectively, these findings suggest that FAK, but not Pyk2, is responsible for coupling TGF-b to breast cancer cell invasion, and as such, predict that targeted inactivation of Pyk2 would be ineffective in altering breast cancer cell invasion stimulated by TGF-b. To test this hypothesis, we utilized two-independent short hairpin RNAs to deplete the expression of Pyk2 in 4T07 cells, whose invasive response to TGF-b was indistinguishable from that displayed by their parental counterparts (Figure 5c ). Collectively, these findings demonstrate that Pyk2 expression is dispensable for TGF-b stimulation of breast cancer invasion, a process dependent upon FAK-mediated turnover of focal adhesion complexes ( Supplementary Movies 1-3) . 18 Upregulated Pyk2 expression couples EMT to metastatic outgrowth stimulated by TGF-b We recently showed that EMT can circumvent breast cancer dormancy and initiate proliferative programs operant in mediating metastatic outgrowth. 4 This scenario is reminiscent of the ability of Pyk2 to enable disseminated breast cancer cells to form macroscopic secondary tumors in the lungs and other tissues in mice (Figures 3 and 4) . Given these parallels, we sought to address the hypothesis that upregulated Pyk2 expression is encompassed in an EMT signature operant in driving metastatic outgrowth. by E-cad and b1 integrin in outgrowth-incompetent (for example, E-cad high, b1 integrin low) or -proficient (for example, E-cad low, b1 integrin high) breast cancer cells. 4 In doing so, we observed Pyk2-deficiency in 4T07 cells to elicit a dramatic upregulation in E-cad expression and prevent TGF-b from inducing that of b1 integrin (Figure 7a ). Despite their elevated basal expression of E-cad, Pyk2-deficient 4T07 cells remained competent to downregulate E-cad expression (Figure 7a ) and stimulate Smad2/3 phosphorylation (Supplementary Figure 5b) in response to TGF-b. Thus, unlike FAK, 18 Pyk2 expression appeared dispensable for general TGF-b signaling, but was essential in coupling TGF-b to b1 integrin expression in outgrowth proficient breast cancer cells. Accordingly, ectopic expression of wild-type E-cad, but not that of a dominant-negative mutant lacking its extracellular domain (DEEcad), 42, 43 prevented TGF-b from inducing Pyk2 expression in a manner that correlated with the ability of wild-type E-cad to repress the expression of b1 integrin in metastatic D2.A1 breast cancer cells (Figure 7b) . 4 Moreover, when propagated in 3D-organotypic cultures, 4T07 cells simultaneously downregulated their expression of E-cad and upregulated that of Pyk2 (Figure 7c) . 4 Importantly, the ability of Pyk2-deficient 4T07 cells to maintain E-cad expression destabilized b1 integrin expression under pulmonary growth conditions (Figure 7c ), an event that we 4 and others 27, 41 have shown to prevent the initiation of metastatic outgrowth. Accordingly, b1 integrin-deficiency elicited an upregulation of E-cad expression that abrogated the ability of TGF-b to induce Pyk2 expression (Figure 7d ). Taken together, these findings highlight the dynamic events required for TGF-b and EMT to initiate the pulmonary outgrowth of disseminated breast cancer cells, a process culminating in diminished E-cad expression, upregulated Pyk2 expression and stabilized b1 integrin expression (Figure 8 ).
DISCUSSION
The switch in TGF-b function from that of a tumor suppressor to a promoter of metastasis is largely thought to reflect the processes associated with EMT. Indeed, EMT elicits the physical interaction of TGF-b receptors with integrins, 31, 33 growth factor receptors 3 and molecules housed within focal adhesion complexes, including FAK and p130Cas. 18, 44 Collectively, these events coalesce in amplifying the invasive potential of breast cancer cells via stimulation several different signaling pathways, including p38 MAPK, NF-kB and Cox-2 (see Taylor et al. 2 and Parvani et al. 45 ). Indeed, based on structural similarities that exist between FAK and Pyk2, 5, 6 we anticipated Pyk2 to have an essential function in driving breast cancer cell invasion stimulated by TGF-b. However, disrupting Pyk2 activity through pharmacological or genetic means failed to alter TGF-b signaling and its stimulation of breast cancer cell invasion, events that are clearly reliant upon FAK ( Figure 5 ). 18 Instead, we defined a novel positive-feedback loop that enables TGF-b to overcome systemic dormancy and initiate the metastatic outgrowth of disseminated breast cancer cells by simultaneously regulating the expression of E-cad, Pyk2 and b1 integrin (Figure 8 ).
Pyk2 expression varied across clonal populations of human MDA-231 breast cancer cells. Moreover, the level of Pyk2 expression directly correlated with the ability of these cells to thrive in pulmonary 3D-organotypic cultures, but not with their ability to invade through Matrigel (Figure 1) . Accordingly, we observed Pyk2 expression to be selectively and specifically upregulated in ex vivo cultures of macroscopic breast cancer metastases (Figure 2) . Moreover, TGF-b-induced EMT significantly enhanced the production of pulmonary tumors, an event that was lacking in Pyk2-deficient cells. Mechanistically, the ability of TGF-b to induce Pyk2 transpires through both Smad4-dependent and -independent pathways. For instance, we previously observed Smad3/4-based signaling to be robust in primary mammary tumors and greatly diminished in their resultant pulmonary metastases. 46 Our current findings indicate that the differential activation of Smad3/4 by TGF-b is due in part to alterations in tissue compliance, such that Smads are strongly stimulated in biomechanically rigid microenvironments and weakly stimulated in their biomechanically compliant counterparts. Thus, our findings imply that metastatic breast cancers must upregulate their expression of Pyk2 before exiting the rigid primary tumor and subsequent blunting of their capacity to activate Smad3/4 upon seeding within the compliant pulmonary microenvironment. As such, it is tempting to speculate that Pyk2 directs an intricate Smad-based EMT program that must be fully operational at the time of metastatic dissemination to avoid succumbing to pulmonary dormancy. Finally, it is important to note that these Pyk2-and EMT-dependent events operant in initiating pulmonary outgrowth must ultimately give way to mesenchymal-epithelial transition (MET), which is required to sustain macroscopic outgrowth of breast metastases. 4, 47 Our findings clearly link Smad4 to increased Pyk2 expression stimulated by TGF-b ( Figure 2) ; however, the simple activation of Smad4 by TGF-b was insufficient to universally elevate Pyk2 levels in all breast cancer cells, particularly those that possess low-grade and nonmetastatic phenotypes (for example, MCF-7 and 67NR cells; Supplementary Figure 1) . For instance, we previously observed metastatic 4T1 cells to poorly activate Smad3/4 as compared with their weakly tumorigenic 67NR counterparts, 44 which failed to elevate Pyk2 expression in response to TGF-b (Supplementary Figure 1) . Likewise, re-expression of Smad4 in Smad4-null MDA-MB-468 cells also failed to couple TGF-b to the expression of Pyk2 (data not shown). These findings suggest that metastatic breast cancer cells selectively express additional Smad4 transcriptional regulators and/or activate alternative effector pathways required to mediate TGF-b stimulation of Pyk2 expression. We previously established Src as an essential factor in mediating the oncogenic activities of TGF-b and its stimulation of breast cancer EMT and metastasis. 18, 48 Along these lines, we show herein that pharmacological inactivation of Src not only decreased the coupling of TGF-b to Pyk2 expression, but also its stimulation of Smad2/3 phosphorylation, thereby potentially implicating Src as an upstream effector operant in coupling TGFb to the activation of Smads and Pyk2. However, at present, we cannot discount a direct inhibitory effect of PP2 on the activity of TGF-b receptors. 49 Nonetheless, it is interesting to note that Smad4 and Src are both essential in mediating the metastasis of breast cancer cells to bone, 50 ,51 which provides a biomechanically rigid microenvironment capable of supporting strong Smaddependent signaling. 52 Collectively, these studies and the findings presented herein implicate Pyk2 as an important mediator of breast cancer metastasis, particularly their ability to reinitiate proliferative programs at sites of secondary tumor formation.
Our conclusion that Pyk2 and E-cad expression are directly related is supported by a recent study that observed overexpression of Pyk2 to elicit the downregulation of E-cad. 14 We show herein that TGF-b controls these interdependent activities, events that coalesce in the stabilization of b1 integrin and production of an outgrowth proficient phenotype (Figure 8 ). 4 Precisely how these effectors reinitiate proliferative programs in disseminated breast cancer cells remains incompletely understood. However, FAK 53 and Pyk2 54 have been detected in the nucleus of malignant cells where they promote Mdm2-mediated ubiquitination and degradation of p53, thereby facilitating enhanced cell proliferation and survival. In response to TGF-b administration, we recently detected both the full-length and FERM domains of Pyk2 and FAK in the nuclei of several human and murine triple-negative breast cancer cell lines (data not shown). Thus, it is tempting to speculate that the activation of b1 integrin promotes the outgrowth of disseminated breast cancer cells via a p53 pathway that relies in part on nuclear localization of Pyk2. Studies are currently underway to address these questions, and to determine the extent to which cytoplasmic and nuclear Pyk2 drive metastatic progression stimulated by TGF-b.
MATERIALS AND METHODS
Cell lines and reagents
Murine D2-HAN (D2.OR and D2.A1) and 4T1 derivatives (67NR, 168FARN, 4T07, 66c14 and 4T1) cells were obtained from Dr Fred Miller (Wayne State University, Detroit, MI, USA), while human MDA-MB-231 cells were purchased from the ATCC (Manassas, VA, USA). All human and murine breast cancer cells were cultured in DMEM supplemented with 10% FBS and 1% Pen/Strep as described previously.
3 Bioluminescent 4T07 and MDA-MB-231 cells were engineered to stably express firefly luciferase as described. 3, 18 Dual-bioluminescent SBE-reporter cells were generated by stably transfecting 4T1 cells with pcDNA3.1-Hygro (Invitrogen, Carlsbad, CA, USA) that constitutively-expressed renilla luciferase under control of the CMV promoter. Afterward, the resulting hygromycin-resistant 4T1 cell populations were stably transfected with pGL4.20-Puro (Promega, Madison, WI, USA) that expressed firefly luciferase under control of the synthetic SBE (4xSmad-binding element) promoter. Clonal MDA-MB-231 cell populations CP1-3 were constructed by transfection with pNifty-CMV-luciferase and clonal isolation under antibiotic selection, while CP4-6 (SCP2-4) were kindly provided by the lab of Dr Joan Massague. 55 MDA-231-SCP-2 cells that lacked Smad4 were previously described. 50 Cellular depletion of b1 integrin and Pyk2 expression was achieved by VSVG lentiviral transduction of pLKO.1 short hairpin RNA vectors (Open Biosystems, Lafayette, CO, USA; Supplementary Table 1) as described. 4, 18 Ectopic expression of wild-type or a dominant-negative E-cad mutant lacking its extracellular domain (DEEcad) 42 ,43 was accomplished as described. 4 Finally, time-lapse microscopy was performed using a Leica DMI6000 over a span of 24 h with the resulting images being captured once every 10 min. In vivo bioluminescent imaging of tumor growth and metastasis Parental (scrambled short hairpin RNA) and Pyk2-deficient 4T07 cells were injected into the lateral tail vein of 4- (Figure 3 ) or 14-( Figure 5 ) week old Balb/C mice. Alternatively, parental and Pyk2-deficient 4T1 cells (1 Â 10 4 cells) were engrafted onto the mammary fat pad of 4-week old Balb/C mice. All bioluminescent images were captured on a Xenogen IVIS-200 (Caliper Life Sciences, Hopkinton, MA, USA), and pulmonary tumor development was assessed by weekly bioluminescent imaging as described. 3, 18, 44 Upon completion of these studies, the mice were euthanized and their metastases were rapidly resected, enzymatically dissociated, and immediately subcultured ex vivo in Zeocin-containing media for 5-7 days, at which point the cells were collected and prepared for immunoblot analysis. Where indicated, metastatic 4T1 lung nodules were quantified by three individuals who were blinded to experimental conditions. All animal procedures were performed in accordance to protocols approved by the Institutional Animal Care and Use Committee for Case Western Reserve University.
Immunoblot assays
Lysates generated from 2D-and 3D-cultures were prepared as described previously. 4 Antibodies used herein are described in the Supplementary Table 2. 3D-organotypic growth assays Human and murine breast cancer were diluted in complete media supplemented with 5% Cultrex (Trevigen, Gaithersburg, MD, USA) and seeded onto solidified Cultrex cushions (50 ml/well) contained in 96-well 18 whose activation is required for TGF-b aberrant signaling and the initiation of EMT programs (left). The consequences of these reactions results in the regulation of several factors that contribute to increased cellular invasiveness, including the upregulation of b3 Integrin and downregulation of E-cad. Subsequent to seeding at a secondary site, downregulated E-cad expression, upregulated Pyk2 expression and the stabilization of b1 integrin are necessary to escape systemic dormancy. 4 Collectively, this interdependent relationship between E-cad, Pyk2 and b1 integrin functions in EMT-initiated pulmonary outgrowth by metastatic breast cancers (right).
plates (1 Â 10 4 cells/cm 2 ). Longitudinal bioluminescent growth assays were performed as described. 3, 4 Pharmacological inhibitors used herein are described in the Supplementary Table 3 .
Cell biological assays
The ability of TGF-b1 (5 ng/ml) to alter serum-induced invasion of MDA-231 and 4T07 cells was analyzed using a Matrigel-coated transwell assay as described. 31 For real-time PCR analysis, 4T07 cells were stimulated with TGF-b1 (5 ng/ml) for varying lengths of time, at which point total RNA was isolated using RNeasy Plus Kit (Qiagen, Valencia, CA, USA). Afterward, total RNA was reverse transcribed using the iScript cDNA Synthesis System (BioRad), and semi-quantitative real-time PCR was conducted using iQ SYBR Green (BioRad, Hercules, CA, USA) as described previously. 18 The oligonucleotide primer pairs used are provided in Supplementary Table 1 . Lastly, direct phalloidin-fluorescence to visualize the actin cytoskeleton was accomplished as described previously. 18, 44 Statistical analyses Statistical values were defined using an unpaired Student's t-test, where a P value o0.05 was considered significant. Statistically significant difference in the overall survival of mice bearing parental or Pyk2-deficient 4T07 tumors was analyzed using a log-rank test. P values for all experiments are indicated.
